Observational data on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a reduction in alcohol use. In this review of three randomized controlled trials (RCTs) (n = 48-151), semaglutide reduced alcohol use, dulaglutide lowered alcohol intake in current drinkers, while exenatide had no significant effect on heavy drinking days. Large RCTs are needed to substantiate the role of GLP-1 RAs in treating alcohol use disorder.
Authors
Patel, Sheel; Blaney, Hanna; Nassar, Sarah; Singal, Ashwani K
Keywords
GLP-1 receptor agonistsalcohol use disorderalcohol-associated liver diseasemetabolic dysfunction